Propanc Biopharma, Inc.
PPCB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.93M
Close$
$0.70
59.5% downside
Current Fair Value
59.5% downsideOvervalued by 59.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.93 Million |
|---|---|
| Enterprise Value | $1.61 Million |
| Earnings per Share | $-17.62 |
| Beta | 3.33 |
| Outstanding Shares | 1,123,709 |
Return
| Return on Equity | -200.63% |
|---|---|
| Return on Assets | -147.60% |
| Return on Invested Capital | -184.01% |
Valuation & Multiples
| P/E Ratio | -0.06 |
|---|---|
| PEG | -0.53 |
| Price to Sales | - |
| Price to Book Ratio | 0.22 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.32 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 5, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Propanc Biopharma, Inc.
2 employees
CEO: James Nathanielsz
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading ...